BioWorld

March 21, 2002

Guilford’s sNDA For Gliadel Wafer Turned Down By FDA

A difference in opinion apparently prompted the FDA to issue Guilford Pharmaceuticals Inc. a non-approvable letter rejecting a supplemental new drug application for use of the Gliadel Wafer in patients with newly diagnosed malignant glioma. (BioWorld Today) Read More

Finding Hot’ Biotech Investments Still Means Looking At Leaders

Despite Dogma, Infectious Prions Hang Out In Mouse Muscle Along With Human, Bovine, Brain Tissue

Schering Buying Collateral In $140M Stock Exchange

Viragen’s Melanoma Treatment: Five-Year Survival Rate Good

Other News To Note

Metabolex, Yamanouchi Enter Diabetes, Obesity Collaboration

Biopure’s Stock Rises on Blood Substitute Phase III Study Data

Today's news in brief

BioWorld

BioWorld briefs for June 12, 2026.

News in brief

BioWorld Asia

BioWorld Asia briefs for June 9, 2026

3D rendering of β2-Adrenergic receptor GPCR protein molecule embedded in lipid bilayer membrane.

Skape Bio unlocks GPCR targets with de novo-designed miniproteins

BioWorld

Modulating G protein-coupled receptors (GPCRs) is one of the major challenges in biomedicine. These are flexible proteins with small, deep binding pockets. The...

New 5-HT2C receptor agonists reported in Hansoh patent

BioWorld Science

Researchers from Jiangsu Hansoh Pharmaceutical Group Co. Ltd. and Shanghai Hansoh Biomedical Co. Ltd. have disclosed tricyclic compounds acting as 5-HT2C receptor...

Pre-disease plasma signature may help redefine lung cancer risk

BioWorld

Researchers have identified a 14-protein blood signature that can predict lung cancer risk as much as five years before diagnosis, and the findings could help...